Cargando…

OVERVIEW ON MRNA VACCINES BEYOND COVID-19

COVID-19 mRNA vaccines: COVID-19 pandemic has made an extraordinary impact on global vaccine technology platform developments. Never in human history have there at least 6 vaccine platforms including: inactivated, protein subunit, VLP and other 3 new platforms i.e., mRNA, viral vector, and DNA, with...

Descripción completa

Detalles Bibliográficos
Autor principal: Ruxrungtham, Kiat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186903/
http://dx.doi.org/10.1016/j.ijid.2023.04.110
_version_ 1785042646380576768
author Ruxrungtham, Kiat
author_facet Ruxrungtham, Kiat
author_sort Ruxrungtham, Kiat
collection PubMed
description COVID-19 mRNA vaccines: COVID-19 pandemic has made an extraordinary impact on global vaccine technology platform developments. Never in human history have there at least 6 vaccine platforms including: inactivated, protein subunit, VLP and other 3 new platforms i.e., mRNA, viral vector, and DNA, with more than 160 vaccine candidates being developed and tested in clinical trials. Nonetheless, among these several vaccine platforms, mRNA vaccine has been proven to be one of the most effective vaccines against COVID-19. There are two mRNA vaccines authorized for emergency use within a year and currently more than 20 mRNA vaccines are in clinical trials. The main advantages of mRNA vaccines are that they are speedily to design and develop, induce strong antibody and T-cell responses, manufacturing faster and at a lower cost. However, one of the major limitations is that it must be stored in cold temperatures. Currently more than billion doses of COVID-19 mRNA vaccines have been given globally. mRNA vaccines will be a key platform for next pandemics preparedness, it is therefore establishing this platform in various regions and LMICs is critical. Beyond COVID-19: A number of viral and cancer mRNA vaccines have been developing even before COVID-19. At least 12 mRNA vaccines against various infectious diseases are now in clinical evaluation, including Chikungunya virus, Cytomegalovirus, Epstein–Barr virus, Human metapneumovirus and parainfluenza virus type3, HIV, Influenza, Nipah, Rabies, Lasa, RSV, Zika, Varicella-zoster virus. Only few are entering phase 3 such as a CMV vaccine, RSV, seasonal influenza. Current mRNA cancer vaccines development, including brain, breast, melanoma, esophagus, lung, ovarian, prostate and solid tumors. Most are aimed for personalized therapy. By 2023, at least 1 viral mRNA vaccine may get approval, whereas a cancer vaccine might take much longer time. Nevertheless, the remaining challenge at the global level is how to truly overcome the vaccine inequity issues in a sustainable way.
format Online
Article
Text
id pubmed-10186903
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101869032023-05-16 OVERVIEW ON MRNA VACCINES BEYOND COVID-19 Ruxrungtham, Kiat Int J Infect Dis S14: Innovation in Infectious Diseases - Adoption and Implementation Date: Saturday, Nov 19, 2022 Time: 14:00-15:30 Venue: Conference Hall #2 (CH2) COVID-19 mRNA vaccines: COVID-19 pandemic has made an extraordinary impact on global vaccine technology platform developments. Never in human history have there at least 6 vaccine platforms including: inactivated, protein subunit, VLP and other 3 new platforms i.e., mRNA, viral vector, and DNA, with more than 160 vaccine candidates being developed and tested in clinical trials. Nonetheless, among these several vaccine platforms, mRNA vaccine has been proven to be one of the most effective vaccines against COVID-19. There are two mRNA vaccines authorized for emergency use within a year and currently more than 20 mRNA vaccines are in clinical trials. The main advantages of mRNA vaccines are that they are speedily to design and develop, induce strong antibody and T-cell responses, manufacturing faster and at a lower cost. However, one of the major limitations is that it must be stored in cold temperatures. Currently more than billion doses of COVID-19 mRNA vaccines have been given globally. mRNA vaccines will be a key platform for next pandemics preparedness, it is therefore establishing this platform in various regions and LMICs is critical. Beyond COVID-19: A number of viral and cancer mRNA vaccines have been developing even before COVID-19. At least 12 mRNA vaccines against various infectious diseases are now in clinical evaluation, including Chikungunya virus, Cytomegalovirus, Epstein–Barr virus, Human metapneumovirus and parainfluenza virus type3, HIV, Influenza, Nipah, Rabies, Lasa, RSV, Zika, Varicella-zoster virus. Only few are entering phase 3 such as a CMV vaccine, RSV, seasonal influenza. Current mRNA cancer vaccines development, including brain, breast, melanoma, esophagus, lung, ovarian, prostate and solid tumors. Most are aimed for personalized therapy. By 2023, at least 1 viral mRNA vaccine may get approval, whereas a cancer vaccine might take much longer time. Nevertheless, the remaining challenge at the global level is how to truly overcome the vaccine inequity issues in a sustainable way. Published by Elsevier Ltd. 2023-05 2023-05-16 /pmc/articles/PMC10186903/ http://dx.doi.org/10.1016/j.ijid.2023.04.110 Text en Copyright © 2023 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle S14: Innovation in Infectious Diseases - Adoption and Implementation Date: Saturday, Nov 19, 2022 Time: 14:00-15:30 Venue: Conference Hall #2 (CH2)
Ruxrungtham, Kiat
OVERVIEW ON MRNA VACCINES BEYOND COVID-19
title OVERVIEW ON MRNA VACCINES BEYOND COVID-19
title_full OVERVIEW ON MRNA VACCINES BEYOND COVID-19
title_fullStr OVERVIEW ON MRNA VACCINES BEYOND COVID-19
title_full_unstemmed OVERVIEW ON MRNA VACCINES BEYOND COVID-19
title_short OVERVIEW ON MRNA VACCINES BEYOND COVID-19
title_sort overview on mrna vaccines beyond covid-19
topic S14: Innovation in Infectious Diseases - Adoption and Implementation Date: Saturday, Nov 19, 2022 Time: 14:00-15:30 Venue: Conference Hall #2 (CH2)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186903/
http://dx.doi.org/10.1016/j.ijid.2023.04.110
work_keys_str_mv AT ruxrungthamkiat overviewonmrnavaccinesbeyondcovid19